Home / Stocks / Gujarat Kidney N Sup Sp L
GKSL

Gujarat Kidney N Sup Sp L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹150.55

Change

-1.16 (-0.76%)

Open

₹152.0

Prev. Close

₹151.71

Day High

₹153.0

Day Low

₹148.41

Volume Analysis

Traded

623,779

Delivered

289,986

Delivery %

46.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (25.0%)

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹157.48 ₹155.24 ₹152.89 ₹150.65 ₹148.3 ₹146.06 ₹143.71
Fibonacci ₹155.24 ₹153.49 ₹152.4 ₹150.65 ₹148.9 ₹147.81 ₹146.06
Camarilla ₹151.81 ₹151.39 ₹150.97 ₹150.65 ₹150.13 ₹149.71 ₹149.29

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+45.54%

1 Week

-4.03%

1 Month

-18.13%

3 Months

-1.58%

6 Months

+5.08%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹38.48

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

4.92%

Net margin 15.87% × asset turnover 0.25x × equity multiplier 1.24x

Company Overview

Sector

Healthcare

Market Cap

₹1,269 Cr

P/E (TTM)

66.8

ROE

11.1%

Book Value

₹33.4

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Gujarat Kidney N Sup Sp L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (25.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

54/100 — Average

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

20

Cash Flow

0

Corporate Governance

56

Momentum

56

Institutional Ownership

15

Business Quality

76

Risk & Volatility

81

Liquidity

49

From Screener.in

  • +Company is expected to give good quarter
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has high debtors of 172 days.
  • −Working capital days have increased from 55.7 days to 91.1 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026.

Audio recording of Q2 FY27 earnings call uploaded on November 5, 2026.

Investor Presentation for scheduled Conference Call on November 05, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 9 12 10 15 13 23 31 34 38
Expenses + 5 7 7 7 8 16 24 26 28
Operating Profit 5 5 3 9 5 7 6 8 10
OPM % 51.65% 39.02% 26.69% 56.49% 39.6% 29.68% 20.6% 24.41% 26.8%
Other Income + 0 0 0 0 0 0 1 1 1
Interest 0 0 0 0 0 1 1 1 1
Depreciation 1 1 1 1 1 1 2 1 2
Profit before tax 4 4 2 7 4 5 5 7 9
Tax % 26.25% 29.72% 16.88% 27.77% 28.54% 26.44% -2.99% 23.56% 23.55%
Net Profit + 3 3 1 5 3 4 5 5 7
EPS in Rs 1 0 0 1 0 0 1 1 1
Raw PDF — — — — — — — — —
YoY Sales growth — — — — 37 97 213 125 195

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 0 5 40 82 126
Expenses + 0 3 24 55 94
Operating Profit 0 2 17 27 32
OPM % — 41.0% 41.0% 33.0% 25.0%
Other Income + 0 1 0 1 2
Interest 0 0 1 2 3
Depreciation 0 0 3 5 6
Profit before tax 0 2 13 21 25
Tax % 0.0% 25.0% 26.0% 21.0% —
Net Profit + 0 2 10 17 20
EPS in Rs 0 0 2 2 2
Dividend Payout % 0.0% 0.0% 0.0% 0.0% —
Sales growth — — 744 104 154

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 0 11 15 237 248
Borrowings + 0 6 8 29 30
Other Liabilities + 4 4 21 16 33
Total Liabilities 4 21 55 298 327
Fixed Assets + 0 14 31 129 149
CWIP 0 0 0 0 0
Investments 0 0 0 12 12
Other Assets + 4 7 24 157 165
Total Assets 4 21 55 298 327
Equity Capital 0 0 11 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 1 14 -4
Cash from Investing Activity + 0 0 -18 -214
Cash from Financing Activity + 0 0 6 228
Net Cash Flow 0 1 2 11
Free Cash Flow 0 2 -5 -98
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0 70 99 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.45% → 71.45%
  Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 16.4% 23.1% 23.1% 21.77%
Promoters 71.45% 71.45% 71.45% 71.45%
FII 10.47% 4.89% 4.89% 6.52%
DII 1.67% 0.56% 0.56% 0.25%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Gujarat Kidney N Sup Sp L (this stock) 1,269 66.8 4.82 11.1%
Kopran Ltd 1,281 32.6 2.44 4.91%
Shalby Limited 1,317 33.6 1.29 2.45%
Anlon Healthcare Limited 1,348 37.8 5.25 18.4%
Fermenta Biotech Ltd. 1,367 29.4 3.27 17.3%
3b Blackbio Dx Ltd. 1,157 19.7 3.33 19.8%
Jagsonpal Pharmaceuticals 1,402 — 5.82 —

Which Mutual Funds Hold Gujarat Kidney N Sup Sp L?

Frequently Asked Questions about Gujarat Kidney N Sup Sp L

Community Sentiment

What are other investors saying about Gujarat Kidney N Sup Sp L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.